• Iptacopan: From C3bBb Biology to Translation

  2026-09-20

  Iptacopan (LNP023) illustrates how selective, reversible factor B inhibition can connect alternative-pathway mechanism, complement-mediated hemolysis assays, animal models, and translational strategy. This thought-leadership perspective interprets the PNH evidence while outlining how researchers can build more decision-ready complement activation studies.

• Valemetostat: From EZH2 Potency to Lymphoma Evidence

  2026-09-19

  Valemetostat (DS-3201) is examined here through an evidence-to-assay framework linking EZH2 biochemistry, chromatin pharmacology, and lymphoma response. Learn how to interpret potency, clinical findings, and research-use handling without confusing molecular inhibition with therapeutic efficacy.

• GVBE Editing of Maternal Alleles in Porcine Oocytes

  2026-09-18

  The reference study introduces germinal vesicle oocyte base editing (GVBE), a strategy for modifying maternal alleles during porcine oocyte maturation before fertilization. Using BE3 mRNA and Dmd-targeting guide RNAs, the authors generated embryos with relatively simple allele patterns and demonstrated a route toward non-mosaic or maternally defined point-mutant founders.

• Caspase-3 Fluorometric Assay Kit: RCC Workflow Guide

  2026-09-18

  Translate treatment-induced cell death into quantitative DEVD-dependent fluorescence with a practical workflow for renal cell carcinoma and broader apoptosis research. The assay pairs rapid microplate readout with inhibitor controls, ROS measurements, and autophagy-focused experiments to distinguish caspase activation from nonspecific loss of viability.

• T7 RNA Polymerase for Translational RNA Workflows

  2026-09-17

  T7 RNA Polymerase converts promoter-bearing DNA into defined RNA for assays spanning transcript stability, RNA structure, antisense design, and research-stage RNA vaccine production. This guide connects practical template engineering and troubleshooting with the DDX21–SIRT7–NAT10 findings reported in colorectal cancer research.

• Doxorubicin: Reproducible Cytotoxicity Workflows

  2026-09-17

  This scenario-based guide helps researchers standardize Doxorubicin exposure, viability readouts, resistance studies, and reagent selection. It explains how SKU A3966 can support interpretable cancer-cell assays through defined handling guidance, literature context, and practical controls.

• Deferasirox in Ferroptosis Research Workflows

  2026-09-16

  Deferasirox is an oral iron chelator that can function as both a translationally relevant iron-depletion tool and a mechanistic control in ferroptosis studies. This guide connects practical dosing, oxygen-aware assay design, and troubleshooting to the METTL16-SENP3-LTF axis in hepatocellular carcinoma.

• Bay 11-7821: Mapping Inflammation to NF-κB

  2026-09-16

  Bay 11-7821 (BAY 11-7082) is a useful perturbation tool for connecting TLR-driven inflammation with NF-κB activity, apoptosis, and cytokine output. This article translates recent Chlamydia psittaci findings into assay-design principles for inflammatory signaling pathway research.

• Q-VD-OPh in Rab14–Parkin Mitophagy Assays

  2026-09-15

  Q-VD-OPh helps researchers separate caspase-dependent cell death from Rab14–Parkin mitophagy, improving interpretation of mitochondrial quality-control experiments. Its cell and brain permeability also supports apoptosis research, neurodegeneration models, and post-cryopreservation viability studies.

• Cy5 Hydrazide: Making Carbonyls Translationally Visible

  2026-09-15

  Carbonyl chemistry offers a practical bridge between nanoparticle formulation, oxidative biology, and translational quality control. This article examines how Cy5 hydrazide can help researchers connect particle behavior with molecular evidence while maintaining realistic boundaries around solvent compatibility, food-grade claims, and clinical readiness.

• PD 0332991 (Palbociclib HCl): CDK4/6 Guide

  2026-09-14

  PD 0332991, also called Palbociclib HCl, is an orally bioavailable CDK4/6 inhibitor that suppresses Rb-positive tumor-cell proliferation through G1 arrest. Its reported biochemical potency, cell-cycle effects, xenograft activity, and handling parameters support controlled research use rather than direct clinical or diagnostic use.

• AT-406 Workflows for Apoptosis Research

  2026-09-14

  AT-406 (SM-406) connects multi-IAP antagonism with practical apoptosis readouts, chemotherapy-sensitization studies, and translational xenograft workflows. This guide emphasizes dosing design, mechanistic time courses, assay controls, and troubleshooting for reproducible cancer research.

• REV1–DHX36 Control of G-Quadruplex Replication

  2026-09-13

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, fork progression, and suppression of single-stranded DNA gaps. The findings establish a two-tier model for G4 tolerance and clarify how REV1 loss amplifies replication stress and ATM/ATR signaling.

• PPM-18 Workflows for NF-κB/iNOS Research

  2026-09-12

  PPM-18 enables pathway-focused studies that separate NF-κB-driven iNOS expression from direct nitric oxide synthase enzyme inhibition. This article provides practical macrophage, inflammation, sepsis, and exploratory bone-remodeling workflows, with controls and troubleshooting guidance for reliable interpretation.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-11

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It produces blunt-ended products and should not be selected when a PCR workflow requires 3′-A overhangs or sticky ends.

8855 records 4/591 page Previous Next 12345 下5页 Last page